Irritable Bowel Syndrome in Primary Care: Rome IV Diagnosis, Red Flags and Treatment by Subtype

Irritable bowel syndrome is a positive diagnosis, not a diagnosis of exclusion. When a patient meets Rome IV criteria (recurrent abdominal pain at least 1 day a week in the last 3 months, tied to defecation or to a change in stool frequency or form, with onset at least 6 months before diagnosis) and has no red flags, the provider makes the diagnosis and limits testing. The ACG 2021 guideline then directs treatment by subtype: soluble fiber, a supervised low FODMAP trial, peppermint oil, tricyclic antidepressants and gut-directed psychotherapy for global symptoms, chloride channel activators or guanylate cyclase agonists for IBS-C, and rifaximin or alosetron for IBS-D.

Assessment: history that makes the diagnosis

A careful history does most of the work. The provider asks about:

• Pain pattern. IBS pain is recurrent and related to bowel movements; it may improve or worsen with defecation. Bloating and distension are common but are not required.
• Stool form and frequency. The Bristol Stool Form Scale gives a shared language: types 1 and 2 are hard, types 6 and 7 are loose or watery.
• Timeline. Symptoms present for 3 months with onset at least 6 months ago.
• Triggers and context. Meals, stress, menstrual cycle, recent gastroenteritis (post-infection IBS), medications such as opioids, magnesium, metformin or anticholinergics.
• Diet. Lactose, fructose, sugar alcohols and high-FODMAP foods.
• Mood and sleep. Anxiety and depression are common and influence both symptoms and treatment choice.
• Red flags, covered below.

Examination is usually normal apart from mild tenderness. A rectal examination is reasonable when constipation, pelvic floor dysfunction or bleeding is part of the picture.

Rome IV diagnostic criteria and subtypes

Rome IV IBS: recurrent abdominal pain, on average at least 1 day per week in the last 3 months, associated with 2 or more of the following:

1. Related to defecation.
2. Associated with a change in stool frequency.
3. Associated with a change in stool form or appearance.

Criteria must be met for the last 3 months, with symptom onset at least 6 months before diagnosis. Rome IV dropped the word "discomfort" used in Rome III; pain is required.

Subtyping by predominant stool form

Subtype is assigned from stool form on days with at least one abnormal bowel movement, ideally off medications that affect bowel habit.

Subtype drives both testing and drug choice, so it should be recorded in the note and revisited, because many patients shift subtype over time.

Red flags that change the pathway

Warning features call for further evaluation, often colonoscopy or specialist referral, before IBS is accepted:

• Rectal bleeding not explained by hemorrhoids or a fissure, or melena.
• Unintentional weight loss.
• Nocturnal symptoms that wake the patient, especially nocturnal diarrhea.
• Iron deficiency anemia or other abnormal laboratory results.
• Symptom onset at an older age; the ACG guideline uses age 45 as the colonoscopy threshold, matching the start of average-risk colorectal cancer screening.
• Family history of colorectal cancer, inflammatory bowel disease or celiac disease.
• Progressive, unrelenting pain, fever or a palpable mass.

The limited work-up: what ACG 2021 recommends

The ACG guideline favors a positive diagnostic strategy: history, examination and a small number of targeted tests, which shortens the time to effective treatment and costs less than serial exclusion testing.

For celiac testing, the ACG celiac guideline uses tissue transglutaminase IgA with a total IgA level, done while the patient is still eating gluten. A basic blood count is reasonable in most patients to look for anemia.

Age-appropriate colorectal cancer screening still applies. Average-risk adults begin screening at 45 under the USPSTF 2021 recommendation, so a 50-year-old with new IBS-type symptoms who has never been screened needs screening regardless of the IBS label.

Treatment for global symptoms (all subtypes)

Management begins with an explanation that IBS is a disorder of gut-brain interaction: real, common and not dangerous. A confident diagnosis itself reduces repeat testing and visits.

Diet and fiber

• Soluble fiber such as psyllium is suggested; insoluble fiber such as wheat bran can worsen bloating and pain. Increase gradually.
• Low FODMAP diet: a limited trial is recommended to improve global symptoms. It has three phases: restriction (responders are usually evident within 2 to 6 weeks), structured reintroduction of individual FODMAP groups, and personalization. A dietitian should guide it, because prolonged strict restriction can cause nutritional deficiencies and disordered eating patterns.

Drug and behavioral therapies

• Peppermint oil is suggested for global symptoms and is generally well tolerated; heartburn is the common side effect.
• Tricyclic antidepressants are recommended for global symptoms, including pain. They are started at low doses at bedtime, below antidepressant doses. Their constipating effect suits IBS-D better than IBS-C.
• Gut-directed psychotherapy, including cognitive behavioral therapy and gut-directed hypnotherapy, is suggested as part of routine care, not as a last resort.
• Antispasmodics are suggested against for global symptoms because the supporting evidence is limited and dated.
• Probiotics are suggested against for global symptoms.

Treatment by subtype

Standard labeled doses for the subtype-specific agents include linaclotide 290 mcg once daily for IBS-C, plecanatide 3 mg once daily, lubiprostone 8 mcg twice daily (approved for IBS-C in women), and rifaximin 550 mg three times daily for 14 days. Linaclotide and plecanatide are taken on an empty stomach and are contraindicated in young children because of dehydration risk; confirm age limits in the current labeling.

Monitoring and follow-up

• Reassess after each defined trial: the low FODMAP restriction phase, a fiber trial, or a new drug. Tricyclics and psychotherapy take several weeks to show benefit.
• Track symptoms with a simple diary of pain days, stool form and stool frequency.
• Re-examine the diagnosis if red flags appear, if symptoms change character, or if the patient reaches screening age.
• Watch for drug effects: dry mouth, sedation and constipation with tricyclics; diarrhea with secretagogues; constipation with alosetron and loperamide.

Referral triggers

• Any red flag, especially bleeding, weight loss, anemia, nocturnal diarrhea or raised fecal calprotectin.
• Positive celiac serology (endoscopic biopsy confirms the diagnosis).
• Refractory IBS-C with suspected pelvic floor dysfunction, for anorectal physiology testing and biofeedback.
• Severe symptoms not responding to first-line therapy, or candidates for alosetron.
• Significant psychological comorbidity, for behavioral health or a gut-directed psychotherapist.

Patient education

• IBS does not cause cancer or inflammatory bowel disease and does not shorten life, but symptoms are real and treatable.
• The diagnosis is made from the pattern of symptoms; more tests are not needed unless new warning signs appear.
• Report blood in the stool, weight loss, waking at night with diarrhea, fever or a big change in symptoms.
• Add soluble fiber slowly with fluid, and expect a few weeks before judging the effect.
• A low FODMAP diet is temporary and works best with a dietitian; the aim is to find personal triggers, not to avoid foods forever.
• Low-dose antidepressants are used for gut pain signaling, not because the symptoms are imagined.
• Family members can help by supporting regular meals, sleep and stress management rather than repeated focus on symptoms.

How the exam tests this

• Ordering a colonoscopy for a young patient without red flags. Under 45 with typical symptoms and no warning features, colonoscopy is the distractor.
• Stool ova and parasites or culture by reflex. Routine pathogen testing is suggested against; celiac serology and fecal calprotectin are the right tests for IBS-D.
• Missing a red flag. A vignette slips in nocturnal diarrhea, iron deficiency anemia or a mother with colon cancer. That patient is not an IBS diagnosis yet.
• Rome III wording. Options mentioning "discomfort" or symptoms for only 6 weeks reflect outdated or wrong criteria.
• Subtype-drug mismatch. Rifaximin for IBS-C or linaclotide for IBS-D is wrong; tricyclics fit IBS-D better than IBS-C.
• Probiotics or antispasmodics as the best answer. Both are suggested against for global symptoms in ACG 2021.
• Polyethylene glycol for global IBS-C symptoms. It softens stool but does not relieve pain; a secretagogue is the guideline answer when global symptoms persist.

Practice question

A 29-year-old woman reports 8 months of crampy lower abdominal pain about 3 days a week that improves after bowel movements, with loose stools 3 to 4 times daily. Symptoms never wake her at night. She denies rectal bleeding, weight loss and recent travel. There is no family history of colorectal cancer or inflammatory bowel disease. Examination shows mild diffuse tenderness. Which of the following is the most appropriate next step?

• A. Colonoscopy with random biopsies
• B. Stool culture and ova and parasite examination
• C. Celiac serology and fecal calprotectin
• D. CT of the abdomen and pelvis

Answer: C. She meets Rome IV criteria for IBS with diarrhea and has no warning features, so the ACG 2021 guideline supports celiac serology and fecal calprotectin to exclude celiac disease and inflammatory bowel disease. Colonoscopy (A) is not routinely recommended in patients under 45 without warning features. Routine stool testing for enteric pathogens (B) is suggested against when there is no travel, outbreak or immune compromise. CT imaging (D) adds radiation and cost without a red flag or examination finding that would justify it.

Key points

Related NPPace guides

• Abnormal Liver Enzymes: Patterns, the First Work-Up and When to Refer
• Chronic Kidney Disease for the NP Exam: KDIGO Staging, Albuminuria, Kidney-Protective Drugs and Dose Adjustment
• Genitourinary Presentations in Primary Care: BPH, Overactive Bladder, Urethritis and When to Refer
• How to Read a Primary-Care Vignette Like a Provider: The 5-Step Method
• AANP vs ANCC: Which NP Certification Exam Should You Take?